Takuya Fukazawa
- Cancer Research top 5%
- Oncology top 5%
- Cancer-related Molecular Pathways 8
- Molecular Biology top 10%
- RNA modifications and cancer 7
- RNA Interference and Gene Delivery 6
- PI3K/AKT/mTOR signaling in cancer 6
- CRISPR and Genetic Engineering 6
- Immunology and Allergy top 10%
- Biotechnology top 5%
- Cancer Research and Treatments 9
-
- Lung Cancer Treatments and Mutations 8
-
- Virus-based gene therapy research 7
- Co-authors
- Yoshio NaomotoNoriaki TanakaYutaka MaedaTomoki YamatsujiToshiyoshi FujiwaraYoshihiko KadowakiJack A. RothMunenori Takaoka
- Journals
- Journal of Biological Chemistry (1 paper)Journal of Clinical Investigation (1 paper)PLoS ONE (2 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Takuya Fukazawa
74 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 97
- Cancer Research 364
- Oncology 545
- Molecular Biology 1.1k
- Immunology and Allergy 79
- Biotechnology 113
Countries citing papers authored by Takuya Fukazawa
This map shows the geographic impact of Takuya Fukazawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takuya Fukazawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takuya Fukazawa more than expected).
Fields of papers citing papers by Takuya Fukazawa
This network shows the impact of papers produced by Takuya Fukazawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takuya Fukazawa. The network helps show where Takuya Fukazawa may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Takuya Fukazawa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 4 | |
| 4 | 2023 | 4 | |
| 5 | 2021 | 4 | |
| 6 | Four cases of gastric cancer in patients with autoimmune gastritis | 2019 | 2 |
| 7 | 2019 | 6 | |
| 8 | Amino acid signaling in the intestine: The roles of glutamine, leucine and arginine | 2014 | 3 |
| 9 | 2013 | 3 | |
| 10 | 2011 | 92 | |
| 11 | Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma. | 2011 | 35 |
| 12 | 2011 | 49 | |
| 13 | 2009 | 4 | |
| 14 | 2008 | 14 | |
| 15 | 2005 | 46 | |
| 16 | 2004 | 26 | |
| 17 | 2004 | 18 | |
| 18 | 2003 | 22 | |
| 19 | 1999 | 64 | |
| 20 | 1999 | 36 |
About Takuya Fukazawa
Takuya Fukazawa is a scholar working on Biotechnology, Cancer Research and Oncology, having authored 75 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Research and Treatments (9 papers), Cancer-related Molecular Pathways (8 papers), Lung Cancer Treatments and Mutations (8 papers), Virus-based gene therapy research (7 papers), RNA modifications and cancer (7 papers), RNA Interference and Gene Delivery (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and CRISPR and Genetic Engineering (6 papers). The work is most often cited by research in Cancer Research (364 citations), Oncology (545 citations) and Molecular Biology (1.1k citations). Takuya Fukazawa has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yoshio Naomoto, Noriaki Tanaka, Yutaka Maeda, Tomoki Yamatsuji, Toshiyoshi Fujiwara, Yoshihiko Kadowaki, Jack A. Roth, Munenori Takaoka, Naoya Kobayashi and Junji Matsuoka. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.